Pharmacovigilance (PV) and post-market surveillance is important to capture the safety profile of a drug. The entire information on a benefit-risk ratio & safety profile is not known until or unless the drug has reached the market and been used in a larger, much wider population. Hence, a systematic approach in monitoring and evaluating the benefit-risk ratio for a product and thus improving its safety profile is important post-market phase. Aggregate reporting systematically collects safety information on adverse drug reactions (ADRs) and submits it to regulatory authorities. Thus, these reports require meticulous analysis of the benefit-risk balance relative to patient safety.
Types of Aggregate Reports
Companies may be required to produce various kinds of aggregate safety reports depending on the stage of product development and regulatory requirements.
Periodic Adverse Drug Experience Reports (PADERs)
PADERs provide reports detailing individual cases that are serious or may be of special interest and follow 21 CFR regulation 314.80. Comprised of five sections that detail cases regarding their seriousness or unexpected/unlisted events, this document must be submitted quarterly for three years after product approval has been received, then annually afterwards; additionally, the US FDA mandates that separate PADERs be submitted for each type of formulation/product type.
Periodic Safety Update Reports (PSURs)
These reports provide regulatory authorities with an updated evaluation of approved medicinal products’ benefit-risk profiles using cumulative safety data.
Periodic Benefit-Risk Evaluation Report (PBRER)
The Periodic Benefit-Risk Evaluation Report (PBRER) builds upon the PSUR by placing greater emphasis on assessing whether therapeutic benefits continue to outweigh potential risks and integrating clinical effectiveness data and safety analysis for regulatory decision-making purposes.
Development Safety Update Report (DSUR)
Amid clinical development, the Development Safety Update Report (DSUR) serves as an annual review of investigational products, summarizing safety findings from ongoing clinical trials while also determining if participants continue to receive appropriate protection.
Addendum Reports These reports capture safety updates available post-data lock point but before submission. Regulatory agencies receive the most up-to-date safety updates available.
Each report serves a distinct function, but collectively they support continuous monitoring of medicinal product safety.
Looking for Expert Aggregate Safety Reporting Services?
Ensure global pharmacovigilance compliance with DDReg Pharma's Aggregate Reporting Services. Our experts prepare and manage PSURs, PBRERs, DSURs, PADERs, and other benefit-risk reports in accordance with ICH, FDA, EMA, and global regulatory requirements.
Explore Aggregate Reporting Services →Challenges in Aggregate Reports and Solutions by DDReg
Some of the key challenges in aggregate reporting include maintaining regulatory compliance and quality with respect to submission timelines, identifying and using the right resources, manually tracking the report from authoring to submission stages, uniformity in update the report or subsequent report, large volumes of data that are prone to errors, ever-changing regulatory updates.
As PV and the drug safety landscape becomes more regulated and complex, the need for skilled, knowledgeable, and subject matter expertise coupled with the ability to interact with multidisciplinary teams, complex data, and stringent timelines is the need.
As the industry and allied organizations move further into the digital space, automation, and technology-driven solutions are tackling these key challenges to deliver more efficient workflow.
Our aggregate reporting specialists have supported safety reporting programs across multiple 130 countries and therapeutic areas, helping pharmaceutical and biotechnology companies prepare regulatory-compliant reports throughout the product lifecycle. Additionally, they create and maintain report timetables and calendars using in-house tools to track and manage reports. Whether it is preparing line listings and tabulation, conducting meticulous medical review, submitting to authorities, and handling agency queries, DDReg’s aggregate reporting capabilities ensures reports are prepared per the most recent regulations and stick to the strict agency timelines.
Global Regulatory Guidelines for Aggregate Reporting
These guidelines are regularly updated by global health authorities. Organizations should always follow the latest versions of ICH, FDA, EMA, MHRA, PMDA, Health Canada, and applicable local regulatory requirements when preparing aggregate reports. Aggregate reporting requirements are guided by internationally accepted standards regional expectations may differ slightly.
Most followed guidelines include:
- ICH E2C(R2) for Periodic Benefit-Risk Evaluation Reports (PBRER);
- ICH E2F for Development Safety Update Reports;
- FDA post-marketing safety reporting requirements.
- EMA Good Pharmacovigilance Practices (GVP) Module VII
- MHRA, Health Canada and PMDA regulations in addition to any other national pharmacovigilance regulations
Organizations marketing products across multiple regions must ensure their aggregate reports meet country-specific submission formats, timelines, and regulatory expectations for submission. Compliance requires continuously keeping abreast of evolving regulations while harmonizing reporting processes to stay compliant globally.
Aggregate Reporting Process Workflow
- Step 1: Data Collection Safety data is gathered from both internal and external sources, including adverse event databases, clinical studies, literature reviews and regulatory correspondence.
- Step 2: Data Validation Validating Your Data before beginning analysis on collected information, it must first be reviewed for accuracy, completeness, consistency and duplicate case detection.
- Step 3: Medical Review and Signal Evaluation To assess overall benefit-risk balance, medical experts review cumulative safety information to identify trends, emerging risks and potential safety signals while simultaneously reviewing benefit-risk balance calculations.
- Step 4: Report Preparation Scientific writers and pharmacovigilance specialists draft reports in accordance with applicable regulatory guidelines, making sure all required sections are complete and well supported.
- Step 5: Quality Review Report Review for Compliance/Submission 6.5 Once complete, this report undergoes meticulous medical, regulatory, and quality assurance reviews to ensure accuracy, consistency and compliance.
- Step 6: Submittance Final reports are submitted to relevant health authorities within their timelines using electronic submission systems.
- Step 7: Regulatory Follow-up Organizations monitor regulatory feedback, respond to health authority inquiries and implement any necessary risk minimization or labeling updates. A standardized workflow helps improve report quality while decreasing submission delays and compliance risks.
Submission Deadlines for Aggregate Reports
Timing can vary based on report type and regulatory authority, but adherence to submission timelines is crucial to compliance and continuous monitoring of a product’s benefit-risk profile.
Deliverables
Aggregate reporting involves much more than simply writing periodic safety reports. Instead, it integrates safety data, scientific analysis, and regulatory documentation into submission-ready deliverables that help health authorities understand a product’s changing safety profile and benefit-risk balance over its lifecycle. When produced accurately and on schedule, these deliverables support regulatory compliance while informing informed decisions during its entire lifespan. Typical deliverables might include:
- PSUR/PBRER reports are comprehensive analyses that assess a product’s overall safety and benefit-risk profile, while
- DSUR reports are annual safety reports which summarize safety issues during clinical development of investigational products.
- PADER Reports, prepared specifically for US FDA regulatory submission, offer periodic reviews of postmarketing adverse drug experiences.
- Benefit-Risk Assessment is a scientific evaluation that uses safety and efficacy data to inform regulatory decision-making processes.
- Signal Evaluation Reports – Comprehensive evaluations of safety signals and identified risks.
- Medical Review & Quality Assurance Documentation – Expert medical reviews to ensure accuracy, consistency, and compliance are performed prior to medical product submissions.
- Submission-Ready eCTD/XML Packages – Electronic submission files prepared according to global regulatory requirements are prepared with seamless submission in mind for easy processing of electronic submission files.
Why Choose DDReg for Aggregate Reporting Services?
Aggregate reporting is an integral component of pharmacovigilance. Unfortunately, managing large volumes of safety data alongside global regulatory change and tight submission deadlines can quickly become complex. That’s where DDReg comes in to add value: we work as part of your team, helping transform safety data into clear, accurate reports that adhere to global regulatory expectations.
Why pharmaceutical companies choose DDReg:
- Comprehensive End-to-End Support – From data collection and medical review through report authoring, quality control, and final submission, our experts manage the entire aggregate reporting process with care and precision.
- Global Regulatory Expertise – Our team has extensive experience preparing PSURs, PBRERs, DSURs and PADERs that meet ICH, FDA and EMA regulatory requirements, among other international regulations.
- Experienced Medical & Safety Writers – Our specialists combine scientific expertise with regulatory know-how to produce reports that are accurate, consistent, and inspection-ready.
- Technology-Enabled Efficiency –We use AI-assisted pharmacovigilance technologies to support data review, duplicate detection, literature screening, workflow automation, and quality checks.
- You Can Trust in Our Quality Reports – Every report undergoes stringent medical, scientific and quality reviews to ensure its accuracy, consistency and regulatory compliance before being submitted for submission.
- Scalable Support at Every Step – Our solutions can meet your business needs and growth plans at every stage, whether they be assistance with one report or ongoing pharmacovigilance services for multiple products and markets. Our support is flexible enough to adapt as your needs evolve.
At DDReg, we believe aggregate reporting services should do more than simply meet regulatory requirements– they should provide meaningful safety insights, facilitate informed decision-making processes, and instil trust throughout its lifespan.
Industries We Serve
Every organization faces its own set of regulatory hurdles and aggregate reporting can often be an inefficient process. At DDReg, we work with life sciences companies across all stages of development and regulatory affairs services requirements for tailored aggregate reporting solutions that best suit their products, development stages and global compliance needs. From creating your initial safety report or managing large portfolios globally – our team of experts ensures you remain compliant while prioritizing patient safety at every step. For these services we support aggregate reporting on:
- Pharmaceutical Companies – Proactively managing periodic safety reports throughout a product lifecycle from launch through post-marketing surveillance is crucial for success.
- Biopharmaceutical & Biosimilar Companies – With global regulatory compliance for biologics and biosimilars comes complex safety reporting requirements for reporting safety information.
- Biotechnology Companies- Assisting innovative biotech organizations build robust pharmacovigilance and aggregate reporting processes as their products move through development.
- Generic Drug Manufacturers – Ensuring timely, compliant aggregate reports to meet post-marketing safety obligations.
- Medical Device and Combination Product Manufacturers – Offering reporting support that addresses regulatory expectations for devices and combination products.
- Clinical Research Organizations (CROs)- Providing assistance with DSURs and aggregate reports throughout clinical development to enable sponsors to meet global reporting requirements.
- Consumer Healthcare & Cosmetic Companies – Supporting post-market safety reporting and pharmacovigilance activities where required by applicable regulations.
No matter the size or product portfolio of your organization, DDReg’s blend of scientific expertise, regulatory knowledge, and technology-enabled processes provides precise aggregate reports that enable compliance and informed safety decisions.
Frequently Asked Questions (FAQs):
Aggregate reports provide pharmaceutical companies with an overall view of product safety that goes beyond individual adverse event cases, helping identify safety trends, support regulatory compliance and make more informed safety decisions throughout a product's lifecycle.
DDReg facilitates the preparation of various aggregate reports, such as PSURs, PBRERs, DSURs, PADERs and other periodic safety documents that meet global regulatory requirements.
Companies often struggle with managing large volumes of safety data from multiple sources while meeting strict deadlines and aligning reports with constantly shifting regulatory edicts.